Abstract
Accurate pathogenicity prediction of missense variants is critical to improve power in genetic studies and accurate interpretation in clinical genetic testing.
Here we describe a new prediction method, MVP, which uses a deep learning approach to leverage large training data sets and many correlated predictors.
Using cancer mutation hotspots and de novo germline mutations from developmental disorders for benchmarking, MVP achieved better performance in prioritizing pathogenic missense variants than previous methods.
Main Text
Missense variants are the most common type of coding genetic variants and are a major class of genetic risk across a broad range of common and rare diseases.
Previous studies have estimated that there is a substantial contribution from de novo missense mutations to structural birth defects [1] [2] [3] and neurodevelopmental disorders [4] [5] [6] . However, only a small fraction of missense de novo mutations are pathogenic 4 . As a result, the statistical power of detecting individual risk genes based on missense variants or mutations is limited 7 . In clinical genetic testing, many of missense variants in well-established risk genes are classified as variants of uncertain significance, unless they are highly recurrent in patients.
Previously published in silico prediction methods have facilitated the interpretation of missense variants, such as CADD 8 , VEST3 9 , metaSVM 10 , M-CAP 11 , and REVEL 12 . However, based on recent de novo mutation data, they all have limited performance with low positive predictive value (Supplementary   Table S1 ), especially in non-constrained genes (defined as ExAC 13 pLI<0.5).
Here we hypothesize that missense variant pathogenicity prediction can be improved in a few dimensions. First, conventional machine learning approaches have limited capacity to leverage large amount of training data compared to recently developed deep learning methods 14 . Second, databases of pathogenic variants curated from the literature are known to have a substantial frequency of false positives 15 , which are likely caused by common issues across databases and therefore introduce inflation of benchmark performance. Developing new benchmark data and methods can help to assess and improve real performance.
Finally, previous methods do not consider gene dosage sensitivity 13, 16 , which can modulate the pathogenicity of deleterious missense variants, as hypomorphic variants are pathogenic only in dosage sensitive genes 6 . With recently published metrics of mutation intolerance, it is now feasible to consider gene dosage sensitivity in predicting pathogenicity. Based on these ideas, we developed a new method, MVP, to improve missense variant pathogenicity prediction.
MVP uses many correlated predictors, which can be broadly grouped into two categories (Supplementary Table S2 ): (a) "raw" features computed at different scales, per base pair (e.g. amino acid constraint score and conservation), per local context (e.g. protein structure and modification) as well as per gene (e.g. gene mutation intolerance, sub-genic regional depletion of missense variants 17 ); (b) deleteriousness scores from selected previous methods. We reason that the variants in constrained genes (ExAC pLI≥0.5) and non-constrained genes may have different modes of action of pathogenicity, therefore, trained our models for the two gene sets separately. We included 38 features for the constrained gene model, and 21 features for the non-constrained gene where we removed most published prediction methods features due to limited prediction accuracy (Supplementary Table S1, S2). MVP uses a deep residual neural network (ResNet) 18 model. There are two layers of residual blocks, consisting of convolutional filters and activation layers, and two fully connected layers with sigmoid output (Supplementary Fig. S1 ). The convolutional filters can exploit spatial locality by enforcing a local connectivity pattern between "neurons" of adjacent layers and identify nonlinear interactions at higher levels of the network. To take advantage of this characteristic, we ordered the predictors based on their correlation, as highly correlated predictors are clustered together ( Supplementary Fig. S2 ). Notably, some protein-related predictors are weakly correlated with previous scores, suggesting that they may include additional information and can help improve the overall prediction accuracy. For each missense variant, we defined MVP score by the rank percentile of the ResNet's raw sigmoid output relative to all 76 million possible missense variants.
We obtained large curated datasets of pathogenic variants as positives and random rare missense variants from population data as negatives for training (Supplementary Table S3 ). Using 6-fold cross-validation on the training set ( Supplementary Fig. S3 To investigate the contribution of features to MVP predictions, we performed cross-one-group-out experiments and used the differences in AUC as an estimation of feature contribution ( Supplementary Fig. S6 ). We found that in constrained gene, conservation scores and published deleteriousness predictors have relatively large contribution, whereas in non-constrained genes, protein structure and modification features and published predictors are most important.
Second, to test the utility in real genetic studies, we obtained germline de novo missense variants (DNMs) from 2645 cases in a congenital heart disease (CHD) study 2 , 3953 cases in autism spectrum disorder (ASD) studies 2, 4, 5 , and DNMs from 1911 controls (unaffected siblings) in Simons Simplex Collection 2, 4, 5 . Since genes with cancer mutation hotspots are relatively well studied in both constrained and non-constrained gene sets, assessment using de novo mutations can provide additional insight with less bias (Supplementary Table S5 ). Because the true pathogenicity of most of the de novo mutations is unknown, we cannot directly evaluate the performance of prediction methods. To address this issue, we calculated the enrichment rate of predicted pathogenic DNMs by a method with a certain threshold in the cases compared to the controls, and then estimated precision and the number of true risk variants (Methods), which is a proxy of recall since the total number of true positives in all cases is a (unknown) constant independent of methods. We compared the performance of MVP to other methods by estimated precision and recall-proxy (Fig. 2) . Based on the optimal thresholds of MVP in cancer hotspot ROC curves, we used a score of 0.7 in constrained genes and 0.75 in non-constrained genes to define pathogenic DNMs (Fig. S7) . In constrained genes, we observed an enrichment of 2.2 in CHD and an enrichment of 1.9 in ASD (Supplementary Table S6 , S7), achieving estimated precision of 0.55 and 0.47 ( Fig. 2A and 2D ), respectively. This indicates that about 50% of the MVP-predicted pathogenic DNMs contribute to the diseases. In non-constrained genes, we observed an enrichment of 1.9 in CHD and 1.4 in ASD (Supplementary Table S6 , S7), respectively, and 0.32 and 0.28 in estimated precision ( Fig. 2B and 2E ). In all genes combined, MVP achieved an estimated precision of 40% for both CHD and ASD ( Fig. 2C and 2F ). The next best methods reached 25% (M-CAP) and 20% (MPC 17 and REVEL) given the same recall-proxy for CHD and ASD, respectively (Supplementary Table S6, S7) . Furthermore, the estimated precision of MVP with DNMs at optimal threshold is much closer to the expected precision based on ROC of cancer hotspots data than the value from VariBench data (Supplementary Figure S8 and Notes), supporting that there is less performance inflation in testing using cancer data. In summary, we developed a new method, MVP, to predict pathogenicity of missense variants. MVP is based on residual neural networks, a supervised deep learning approach, and was trained using a large number of curated pathogenic variants from clinical databases, separately on constrained genes and nonconstrained genes. Using cancer mutation hotspots and de novo mutations from CHD and ASD, we showed that MVP achieved overall better performance than published methods, especially in non-constrained genes. Nevertheless, the fraction of pathogenic variants among de novo missense variants in nonconstrained genes is low in both CHD and ASD, leading to relatively poor performance by all methods. MVP achieved substantially better performance than other methods in these genes, partly attributed to inclusion of protein structure-based predictors (Supplementary Figure S6B) . Further improvement in protein structure prediction and the utilization of protein structure in the model 22 would be the key to improve MVP. Finally, all methods are limited by the size and the potentially high false positive rate of the training data.
Systematic efforts such as ClinVar 23 will eventually produce better training data to improve prediction performance.
ULRs.
Software and data for implementing MVP are available from https://github.com/ShenLab/missense ; Precomputed MVP pathogenicity score for all possible missense variants in canonical transcripts on human hg19 can be downloaded from:
https://www.dropbox.com/s/bueatvqnkvqcb54/MVP_scores_hg19.txt.bz2?dl=0 Table S3 ).
Methods and materials

Training data sets
Testing data sets
We have three categories of testing data sets (Supplementary Table S3 ). We tested the performance in constrained genes (ExAC pLI ≥ 0.5) and nonconstrained gene (ExAC pLI < 0.5) 13 separately.
To focus on rare variants with large effect, we selected ultra-rare variants with MAF <10 -4 based on gnomAD database to filter variants in both training and testing data sets. We applied additional filter of MAF < 10 -6
for variants in constrained genes in both cases and controls for comparison based on a recent study 17, 27 .
Features used in MVP model
MVP uses many correlated features as predictors (Supplementary Table S2 ).
There are six categories: (1) Table S2 ).
Deep learning model
MVP is based on a deep residual neural network model (ResNet) 18 for predicting pathogenicity using the predictors described above. Fig. S1 ).
In training, we randomly partitioned the synthetic training data sets into two parts, 80% of the total training sets for training and 20% for validation. We trained the model with batch size of 64, used adam 56 optimizer to perform stochastic gradient descent 57 with logarithmic loss between the predicted value and true value. After one full training cycle on the training set, we applied the latest model weights on validation data to compute validation loss.
To avoid over fitting, we used early stopping regularization during training. We computed the loss in training data and validation data after each training cycle and stopped the process when validation loss is comparable to training loss and do not decrease after 5 more training cycle, and then we set the model weights using the last set with the lowest validation loss. We applied the same model weights on testing data to obtain MVP scores for further analysis.
Previously published methods for comparison
We compared MVP score to 13 previously published prediction scores, namely, M-CAP 11 
Normalization of scores using rank percentile
For each method, we first obtained predicted scores of all possible rare missense variants in canonical transcripts, and then sort the scores and converted the scores into rank percentile. Higher rank percentile indicates more damaging, e.g., a rank score of 0.75 indicates the missense variant is more likely to be pathogenic than 75% of all possible missense variants.
ROC curves
We plotted Receiver operating characteristic (ROC) curves and calculated Area Under the Curve (AUC) values in training data with 6-fold cross validation ( Supplementary Fig. S3 ), and compared MVP performance with other prediction scores in curated benchmark testing datasets ( Supplementary Fig. S4 ) and cancer hotspot mutation dataset (Fig. 2) . For each prediction method, we varied the threshold for calling pathogenic mutations in a certain range and computed the corresponding sensitivity and specificity based on true positive, false positive, false negative and true negative predictions. ROC curve was then generated by plotting sensitivity against 1 -specificity at each threshold.
Optimal points based on ROC curves.
We define the optimal threshold for MVP score as the threshold where the corresponding point in ROC curve has the largest distance to the diagonal line (Supplementary Figure S7) . Based on the true positive rate and false positive rate at the optimal points in ROC curves, we can estimate the precision and recall in de novo precision-recall-proxy curves (Supplementary Figure S8 and Supplementary Notes).
Precision-recall-proxy curves
Since de novo mutation data do not have ground truth, we used the excess of predicted pathogenic missense de novo variants in cases compared to controls to estimate precision and proxy of recall. For various thresholds of different scores, we can calculate the estimated number of risk variants and estimated precision based on enrichment of predicted damaging variants in cases compared to controls. We adjusted the number of missense de novo mutation in controls by the synonymous rate ratio in cases verses controls, assuming the average number of synonymous as the data sets were sequenced and processed separately) (Table S10) , which partly reduced the signal but ensures that our results were not inflated by the technical difference in data processing.
Denote the number of cases and controls as N1 and N0, respectively; the number of predicted pathogenic de novo missense variants as M1 and M0, in cases and controls, respectively; the rate of synonymous de novo variants as S1 and S0, in cases and controls, respectively; technical adjustment rate as ; and the enrichment rate of variants in cases compared to controls as R.
We first estimate by:
Then assuming the rate of synonymous de novo variants in cases and controls should be identical if there is no technical batch effect, we use to adjust estimated enrichment of pathogenic de novo variants in cases compared to the controls by: 
